Entities / Company
Takeda Pharmaceutical Company.
Japanese pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 114
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Christophe Weber was appointed as President and CEO of Takeda Pharmaceutical Company.Well supported4 reports
-
Several individuals, including Yoshiaki Fujimori, were appointed to Takeda Pharmaceutical Company's Nomination and Compensation committees.Speculative1 report
-
Keros Therapeutics and Takeda signed a license agreement for elritercept, excluding Macau and mainland China from commercialization.Some support3 reports
-
The FDA granted 510(k) clearance for HyHub and HyHub Duo devices on July 21, 2025. Kristina Allikmets is senior vice president for Takeda.Some support1 report
No events began in the chosen period. Widen it, or reset.
Connections
The 1 strongest of 114, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
ADMA Biologics (United States) Operational
ADMA Biologics and Takeda Pharmaceutical Company actively compete as leading players in the plasma-derived products sector.
History
Events by the month they beganJune 2026
5 events- Protagonist Therapeutics and Takeda Pharmaceutical Company entered a strategic partnership regarding the Rusfertide drug candidate, while Citi initiated coverage with a Buy rating.
- Christophe Weber was appointed as President and CEO of Takeda Pharmaceutical Company.
- Several individuals, including Yoshiaki Fujimori, were appointed to Takeda Pharmaceutical Company's Nomination and Compensation committees.
- Keros Therapeutics and Takeda signed a license agreement for elritercept, excluding Macau and mainland China from commercialization.
- The FDA granted 510(k) clearance for HyHub and HyHub Duo devices on July 21, 2025. Kristina Allikmets is senior vice president for Takeda.